Sequencing of targeted therapies in HER2-positive metastatic breast cancer Figure 2 from Singh et al. British Journal of Cancer (2014) 111, 1888-1898.

Slides:

Advertisements

Similar presentations

KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.

Advertisements

New Developments in Cancer Treatment Dulcinea Quintana, MD.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Expressing Surface Proteins to Target Cancer Cells Joe and Bobby.

Overview of Targeted Therapy Mechanisms November 11, 2011 Targeted Therapies and Biological Therapies SIG.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

Schema for a human microbiome study

Fig. 8. Response to aromatase inhibitor and cyclin dependent kinase inhibitor in metastatic hormone receptor+, HER2 negative breast cancer. In this 29-year-old.

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.

Ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody.

Ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody.

Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials Pippa Newell, Augusto Villanueva, Josep M. Llovet

سرطان الثدي Breast Cancer

Inhibitor of MAP kinase activation blocks colon cancer growth

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Figure 1 Current treatments for PNETs

Figure 7 Clinical options for HCC therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Focus on breast cancer Cancer Cell

Figure 4 Possible combination therapies CDK4/6 inhibitors

The PI3K/Akt signalling and its activation in cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The hallmarks of adenovirus infection

The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.

Schematic diagram of antibody drug conjugate

Figure 1 A schematic representation of the HER2 signalling pathway

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 6 Combination therapy for HCC

The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British.

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

(A) An overview of the JAK/STAT signalling pathway.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Molecular approaches to HER2 targeted therapy

An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT signalling networks in pancreatic cancer Figure 1 from Eser et al. British Journal.

Model of the function of TBX2 in RMS.

Figure 2 from Sancho et al.

The cancer stem cell concept in cancer progression and metastasis

The putative genomic evolution of prostate cancer from normal epithelium to castrate-resistant, metastatic cancer Figure 2 from Mitchell and Neal British.

Figure 1 from B Zhu British Journal of Cancer (2015) 112, ; doi: /bjc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

A hypothetical scheme targeting autophagy for glioblastoma sensitisation during radio-chemotherapy with TMZ Figure 1 from Michael I Achilleas G and.

Figure 2 Site of action of checkpoint inhibitors and agonists being

Targeting T Cell Co-receptors for Cancer Therapy

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

The Changing Field of Melanoma: Ipilimumab.

Figure 1 from M Holderfield

Molecular features of the colon during homeostasis and carcinogenesis

Figure 1 from T Schenk et al.

Nat. Rev. Endocrinol. doi: /nrendo

Fbxw7 ablation in LICs for CML sensitises the cells to imatinib by preventing quiescence. Figure 2 from S Takeishi British Journal of Cancer (2014) 111,

HDACs class I, II, IV mutations in human cancer

In melanoma tumours expressing the BRAFV600E oncogene RAF inhibitor treatment decreases ERK activation resulting in tumour regression and increased survival.

Figure 1 Mechanisms of action of immunotherapy modalities

Mitochondrial priming model

Nat. Rev. Cardiol. doi: /nrcardio

Spectrum of cellular processes regulated by AXL activity

Figure 1 from D’Incalci et al.

Involvement of actin cytoskeletal reorganisation in EMT

The F-box protein Fbxw7 is required for maintenance of normal stem cells. Figure 1 from S Takeishi British Journal of Cancer (2014) 111, ; doi: /bjc

Target antigens for ADCs in solid tumours

Macrophage differentiation and their role in tumourigenesis

Model of EphA/ephrin-A expression in GBM.

Focus on breast cancer Cancer Cell

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Presentation transcript:

Sequencing of targeted therapies in HER2-positive metastatic breast cancer Figure 2 from Singh et al. British Journal of Cancer (2014) 111, 1888-1898 doi:10.1038/bjc.2014.388 Several approaches exist to target Eph receptors. Kinase inactivating strategies include kinase inhibitors or blocking peptides or antibodies. Kinase activating strategies include ligand stimulation, activating antibodies or ligand peptide mimetics Strategies to deliver toxic payloads following receptor activation and internalisation include coupling of cytotoxic agents or radionuclides to Eph monoclonal antibodies. © 2014 Cancer Research UK.